IBRX SECURITIES FRAUD: Hagens Berman, National Trial Attorneys, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Published August 9, 2023

SAN FRANCISCO, CA / ACCESSWIRE / August 9, 2023 / Hagens Berman urges ImmunityBio, Inc. (NASDAQ:IBRX) investors who suffered substantial losses to submit your losses now.

Class Period: May 23, 2022 - May 10, 2023

Lead Plaintiff Deadline: Aug. 29, 2023

Visit: www.hbsslaw.com/investor-fraud/ibrx

Contact An Attorney Now: IBRX@hbsslaw.com


ImmunityBio, Inc. (IBRX) Securities Fraud Class Action:

The litigation focuses on ImmunityBio's statements about the manufacturing and commercial prospects for its lead product candidate (Anktiva) for the treatment of patients with certain non-muscle invasive bladder cancer.

The complaint alleges that Defendants made false and misleading statements and failed to disclose that: (1) ImmunityBio conducted insufficient due diligence to discover, or else discovered and ignored, GMP deficiencies at its third-party contract manufacturing organizations ("CMOs") for Anktiva; (2) one or more of the company's third-party CMOs for Anktiva did in fact suffer from GMP deficiencies; (3) the deficiencies were likely to cause the FDA to reject the Anktiva BLA in its present form; and (4) accordingly, ImmunityBio overstated the regulatory approval prospects for the Anktiva BLA.

Investors learned the truth on May 11, 2023, when ImmunityBio announced the FDA had rejected the BLA in its present form, disclosing that "[t]he deficiencies relate to the FDA's pre-license inspection of the Company's third-party contract manufacturing organizations."

This news drove the price of ImmunityBio shares crashing 55% lower on May 11, 2023.

"We're focused on investors' losses and proving ImmunityBio misrepresented its GMP in light of the FDA's findings," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in ImmunityBio and have substantial losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding ImmunityBio should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email IBRX@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

View source version on accesswire.com:


News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.